ORGO
NASDAQ · Biotechnology
Organogenesis Holdings Inc
$0.84
-0.03 (-3.46%)
Open$0.90
Previous Close$0.87
Day High$0.90
Day Low$0.80
52W High$7.08
52W Low$0.73
Volume—
Avg Volume1.24M
Market Cap114.73M
P/E Ratio—
EPS$-0.69
SectorBiotechnology
Analyst Ratings
Strong Sell
7 analysts
Price Target
+894.2% upside
Current
$0.84
$0.84
Target
$8.35
$8.35
$5.30
$8.35 avg
$10.56
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 591.69M | 549.09M | 163.70M |
| Net Income | 38.84M | 32.44M | 15.03M |
| Profit Margin | 6.6% | 6.2% | 9.2% |
| EBITDA | 62.89M | 55.44M | 20.76M |
| Free Cash Flow | — | — | 17.26M |
| Rev Growth | +7.8% | +7.8% | +17.3% |
| Debt/Equity | 0.05 | 0.05 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |